Vaccination soon open to the general population

A much-awaited stage of the vaccination campaign was announced, as the Minister of Health and Social Services, Christian Dubé, confirmed that appointments for the general population will begin shortly.

As of April 30th, depending the goal is to open vaccination to everyone within two weeks.

Opening of making appointmentsAge groupTarget population vaccinated (75%)First doseScheduled meetings for 1 doseAppointment to take to reach the target
30 April50 to 59866 387475 737129 643261 007
May 345 to 49396 921158 25861 887176 776
May 540 to 44439 57499 55648 150291 868
May 735 to 39423 54387 03939 974296 530
May 1030 to 34415 42974 09034 891306 448
May 1225 to 29413 98269 93929 316314 727
May 1418 to 24498 34867 58828 923401 837

Large confirmed deliveries of vaccine doses are expected during the next few weeks and vaccinations for the general population will begin shortly. The total number of planned doses is 2,517,080, broken down as follows:

  • 594,770 doses during the week of May 3;
  • 458,640 doses during the week of May 10;
  • 458,640 doses during the week of May 17;
  • 458,640 doses during the week of May 24;
  • 546,390 doses during the week of May 31.

“After opening vaccination to all priority groups, we are finally able to start making appointments for the rest of the adult population. This is great news. I am very proud of what we have accomplished so far, and also of the public’s response. Vaccination is the best solution that will allow us to return to normal life. Several weeks will still be needed to protect a sufficiently large part of the population, but we are approaching the goal. » said Christian Dubé, Minister of Health and Social Services  

  • Over the past few days, appointment scheduling has been extended to people with a disability, as well as one caregiver per person in this clientele, and pregnant women.
  • Following the confirmation, on April 27, of the death of a person following a thrombosis with thrombocytopenia (VIPIT) which occurred after the administration of a viral vector vaccine against COVID-19, namely the vaccine AstraZeneca (Covishield), the public is advised to take into consideration that these cases remain very rare. The benefits of the vaccine are considered to far outweigh the risks. However, it is important to remember that people who have received this vaccine should consult a doctor or Info-Santé promptly if, particularly within 4 to 20 days following vaccination, the following symptoms appear:
    • shortness of breath, pain in the chest, leg swelling, or stomach pain;
    • a severe headache or a headache that has lasted for a few days, blurred vision or bruising on the skin.